Optimizing immunotherapy: Rationale for a combination therapy approach
ESMO 2017: ESMO COLLOQUIUM
Optimizing immunotherapy: Rationale for a combination therapy approach
Invited Oral Presentation at the annual meeting of the European Society of Medical Oncology (ESMO) Congress, Madrid, September 2017
A review focusing on some of these studies has been published in Drug Resistance Updates: Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
Link: www.sciencedirect.com/science/article/pii/S1368764619300330
PDF file: ESMO 2017
